Cell News and Research

RSS

Isolating and concentrating cells from whole blood: an interview with Victor Ugaz

There are several reasons for this. One is because analysis involving different kinds of blood cells may require you to be able to separate red blood cells from white blood cells, or plasma from whole blood etc.

21 Sep 2012

Caltech biologists gain new insight into migrating cells

At any given moment, millions of cells are on the move in the human body, typically on their way to aid in immune response, make repairs, or provide some other benefit to the structures around them. When the migration process goes wrong, however, the results can include tumor formation and metastatic cancer. Little has been known about how cell migration actually works, but now, with the help of some tiny worms, researchers at the California Institute of Technology (Caltech) have gained new insight into this highly complex task.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

Iron transport may contribute to diabetes

Scientists have been trying to explain the causes of diabetes for many years. Researchers at the University of Copenhagen and Novo Nordisk A/S have now shown that the increased activity of one particular iron-transport protein destroys insulin-producing beta cells. In addition, the new research shows that mice without this iron transporter are protected against developing diabetes.

21 Sep 2012

Mathematical modeling can help treat several diseases

Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that continue to challenge scientists across the world.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

First extensive analysis of Allen Human Brain Atlas

Scientists at the Allen Institute for Brain Science reported in the latest issue of the journal Nature that human brains share a consistent genetic blueprint and possess enormous biochemical complexity. The findings stem from the first deep and large-scale analysis of the vast data set publicly available in the Allen Human Brain Atlas.

21 Sep 2012

Researchers develop cranial neural crest cell lines

Researchers have successfully developed a stable population of neural crest cells derived from mice that can be grown in large quantities in the laboratory and that demonstrates the potential to develop into many different cell types needed throughout the body.

21 Sep 2012

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

Systems biologist to pursue research into next-generation genome sequencing technology

Systems biologist Edward Marcotte has received a $2.5 million grant from the National Institutes of Health to pursue cutting-edge research in the area of genome sequencing technology.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Sweet success healing diabetic foot ulcers

Scientists have harnessed the antibacterial properties of Manuka honey to speed healing of neuropathic diabetic foot ulcers.

20 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

The Institute for Translational Medicine and Therapeutics' 7th Annual International Symposium (ITMAT) will be held October 16 and 17 at the Perelman School of Medicine, University of Pennsylvania.

20 Sep 2012

PNAS: Ras proteins bring tension to the phosphate chain

Proteins accelerate certain chemical reactions in cells by several orders of magnitude. The molecular mechanism by which the Ras protein accelerates the cleavage of the molecule GTP and thus slows cell growth is described by biophysicists at the Ruhr-Universit-t Bochum led by Prof. Dr. Klaus Gerwert in the Online Early Edition of the journal PNAS.

20 Sep 2012

UK scientists make breakthrough in new method of brain tumour diagnosis

UK scientists have made a breakthrough in a new method of brain tumour diagnosis, offering hope to tens of thousands of people.

20 Sep 2012

Molecular disruptions in granule cells cause epileptic seizures in mice

Scientists have discovered the first direct evidence that a biological mechanism long suspected in epilepsy is capable of triggering brain seizures – opening the door for studies to seek improved treatments or even preventative therapies.

20 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Tel Aviv University researcher discovers homing device that draws cancer

The process of metastasis, by which cancer cells travel from a tumor site and proliferate at other sites in the body, is a serious threat to cancer patients. According to the National Cancer Institute, most recurrences of cancer are metastases rather than "new" cancers.

20 Sep 2012